# IVPT IN VITRO PERMEATION TEST

Howard I. Maibach, M.D.

Department of Dermatology
School of Medicine
University of California
San Francisco, California

### KEY BIOLOGIC | PHARMACOLOGIC QUESTIONS

1) IVPT VALUE FOR BIOEQUIVALENCE?

- 2) IVPT COMPARED TO IN VIVO?
  - DOES IT MATTER?

#### "THE BEGINNING"

GEORGE BURCH
TULANE MEDICAL SCHOOL
INTERNAL MEDICINE
PHYSIOLOGY – TEWL

### BEGINNING – CHEMICAL WARFARE

IVPT - WORLD WAR II - UNITED KINGDOM

R. TREGEAR: PHYSICAL FUNCTIONS

OF SKIN, ACADEMIC

PRESS, 1966

OLD AND NEW TESTAMENT COMBINED.

#### **BIBLIOGRAPHY**


#### **SCHAEFER**

HANDBUCH DER HAUT BOOK 14B 1981
 40 PAGES – REFERENCES

• SKIN BARRIER- KARGER, 1996

#### FIRST CHAMBERS

#### **TRAGEAR**



Diffusion cells, as used for the measurement of penetration by isotopelabelled chemicals though (A) skin or (B) epidermal membranes.

#### FLOW THROUGH SYSTEMS

ANSWORTH: J SOC COS CHEM, 11:69,

1960

MARZULLI: J INVEST DERM, 39: 387,


1962

BRONAUGH: IN VITRO ABSORPTION,

CRC PRESS, 1991

### FLOW THROUGH CELL: PERFUSION RATE

#### **TREGEAR**



The penetration of tri-n-butyl phosphate through perfused pig skin, related to the perfusion rate. The results from eight experiments are included.

## FLOW THROUGH RATE: VS. STATIC

Wm. CRUTCHER: J INVEST DERM,

53: 264, 1969

- LIMITED DATA | POWER
- LIMITED FLOW RANGES | SOLUBILITIES

#### SKIN SURROGATES

- MEMBRANES
  - O NUEPANE PHARMACEUTICS, 12:152, 2020

- HUMAN SKIN EQUIVALENTS (HSE)
  - BOUWSTRA ADVANCED DRUG DELIVERY REV,
     2021

#### **CELL DESIGN**

#### STEPHEN FRANTZ

[B. KEMPPAINEN: METHODS FOR SKIN

ABSORPTION, CRC PRESS,

2000]

#### METRICS - SKIN 'NORMALITY'

BRONAUGH TRITIATED WATER

NANGIA TEWL (TRANSEPIDERMAL

WATER LOSS), INT J

PHARM, 170: 33, 1998

ELECTRICAL PROPERTIES:

INPEDENCE | CAPACITANCE

### MASS BALANCE SKIN COMPARTMENTS

- SURFACE RESIDUE (NOT ABSORBED)
- STRATUM CORNEUM TAPE STRIPPING (PERFECT NUMBER?)
- STRATUM CORNEUM
- EPIDERMIS
  - DERMIS
  - RESERVIOR

IDEAL: > 95% APPLIED DOSE

[BUCKS: J INVEST DERM, 90:29, 1988]

#### SEPARATING SKIN LAYERS

- STRATUM CORNEUM
- EPIDERMIS
- DERMIS

[ZOU: ARCH DERMATOL RES, 310:1, 2018]

#### REGIONAL VARIATION

#### NORMALIZE TO OTHER SITES

[GUY: IN <u>BRONAUGH'S</u>

PERCUTANEOUS ABSORPTION, 2<sup>ND</sup> ED.,

Page 461]

#### **METABOLISM**

KAO, JOHN: 'COLD' CHEMISTRY vs.

'RADIOLABELS'

KEMPPAINEN, B: METHODS FOR SKIN

ABSORPTION,

CRC PRESS, 1990

**PAGE 192** 

#### **METABOLISM**

#### FRESH vs. FROZEN SKIN

- VIABILITY ASSAYS (GLUCOSE)
- TISSUE CULTURE IN RESERVOIR
- MAN vs PIG!
- CHEMICAL SPECIFICITY ?

# VITRO vs VIVO MAN ?

#### AGREEMENT - WITH - IN VIVO HUMAN DATA

• VITRO | VIVO RATIO (ALL DATA) 0.18 TO 19.7

• VITRO | VIVO RATIO (HARMONIZED) 0.58 TO 1.28

#### **AWAITS REPLICATION**

[LEHMAN: SKIN PHARMACOL PHYSIOL, 24:224, 2011]




Fig. 1. IVIV ratios of total absorption for all 92 data sets plotted on log-log scale. The IVIV ratios ranged from 0.18 to 19.7, with an overall mean of 1.6. Solid line: ideal 1:1 correlation. Dashed lines: ±3-fold difference from ideal.




Fig. 2. IVIV ratios of total absorption for 11 fully harmonized data sets plotted on log-log scale. The IVIV ratios ranged from 0.58 to 1.28, with an overall mean of 0.96. Line: ideal 1:1 correlation.

#### PROTEIN BINDING

STRATUM CORNEUM- SUBSTANTIVITY

**EPIDERMIS** 

**DERMIS** 

FAT- ?

```
[MENCZEL J INVEST DERM, 54: 386, 1970]
```

[HUI J APPLIED TOX, 33:157, 2013]

### IN VIVO COMPLEXITY 20+ STEPS!

LAW: AM J CLIN DERMATOL, 2020 FEB; 21(1): 85-9

RELEVANT PHYSICO-CHEMICAL PROPERTIES (PARTICLE—SIZE | MOLECULAR WEIGHT, LIPOPHILICYT, PH, Pka, PARTITION **COEFFICIENT** VEHICLE | FORMULATION CONDITIONS OF DRUG EXPOSURE (DOSE, DURATION, SURFACE AREA, EXPOSURE FREQUENCY SKIN APPENDAGES (HAIR FOLLICLES, GLANDS) AS SUB-ANATOMICAL PATHWAYS SKIN APPLICATION SITES (REGIONAL VARIATION IN **PENETRATION** 

6	POPULATION VARIABILITY (PREMATURITY, INFANTS, AGED
7	SKIN SURFACE CONDITIONS (HYDRATION, TEMPERATURE, PH
8	SKIN HEALTH AND INTEGRITY (TRAUMA, SKIN DISEASES)
9	SUBSTANTIVITY AND DBINDING TO DIFFERENT SKIN
	COMPONENTS
10	SYSTEMIC DISTRIBUTION AND SYSTEMIC TOXICITY
11	EXFOLIATION
12	WASHING-OFF AND WASHING - IN
13	RUBBING   MASSAGING
14	TRANSFER TO OTHERS (FROM HUMAN TO HUMAN AND HARD SURFACE TO HUMAN)

15	VOLATILITY
16	METABOLIC BIOTRANSFORMATION   CUTANEOUS METABOLISM
17	PHOTOCHEMICAL TRANSFORMATION   AND PHOTOSENSITIVITY
18	EXCRETION PHARMACOKINETICS
19	LATERAL SPREAD
20	CHEMICAL METHOD OF DETERMINING PERCUTANEOUS ABSORPTION

### CLINICAL RELEVANCE DISEASE | DAMAGED SKIN

• GATTU: SKIN PHARM PHYS

23: 171, 2010

• GATTU: SKIN PHARM PHYS

24: 2, 2011

APPROXIMATING 2 FOLDS

• BARRIERS - ALL SKIN COMPARTMENTS

#### IN VIVO HUMAN DATA BASES

#### OPPORTUNITIES FOR IN VITRO 'VALIDATION'

- CORTICOSTEROID VASOCONSTRICTION
  - RB STOUGHTON
- TRANSDERMALS
  - S. FARAHMAND, INT'L J PHARMACEUTICS,
     (2009), 367 (1-2), pp 1-15

#### **GUIDANCES**

- GROUP "DISCUSSIONS" |
   JUDGEMENTS
  - OECD
  - EPA

DATA WILL BE FINAL ARBITER!

